Albireo Pharma, Inc. financial data

Location
10 Post Office Square, Suite 502 South, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Biodel Inc (to 11/2/2016)
Latest financial report
10-Q - Q3 2022 - Nov 8, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 589 % -33.6%
Quick Ratio 4.59 %
Debt-to-equity 107 % +56.7%
Return On Equity -97.6 % -218%
Return On Assets -47.1 % -159%
Operating Margin -214 % +82.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20.7M shares +7.38%
Common Stock, Shares, Outstanding 20.7M shares +7.35%
Common Stock, Value, Issued 207K USD +7.25%
Weighted Average Number of Shares Outstanding, Basic 19.7M shares +2.06%
Weighted Average Number of Shares Outstanding, Diluted 19.7M shares +0.02%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 57.4M USD +433%
Cost of Revenue 612K USD +42%
Research and Development Expense 88.7M USD +8.22%
Operating Income (Loss) -123M USD +7.86%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -37.8M USD -162%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -131M USD -174%
Earnings Per Share, Basic -6.69 USD/shares -165%
Earnings Per Share, Diluted -6.63 USD/shares -166%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 222M USD -15.3%
Accounts Receivable, after Allowance for Credit Loss, Current 2.03M USD +55.2%
Inventory, Net 3.15M USD +1507%
Other Assets, Current 2.67M USD
Assets, Current 239M USD -12.2%
Property, Plant and Equipment, Net 1.3M USD +68.1%
Goodwill 17.3M USD 0%
Other Assets, Noncurrent 13.8M USD +112%
Assets 321M USD +8.36%
Accrued Liabilities, Current 25.4M USD +21.5%
Liabilities, Current 37.8M USD +14.1%
Other Liabilities, Noncurrent 9.64M USD +207%
Liabilities 221M USD +92.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 8.21M USD
Retained Earnings (Accumulated Deficit) -421M USD -45.2%
Stockholders' Equity Attributable to Parent 100M USD -44.9%
Liabilities and Equity 321M USD +8.36%

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 60M shares 0%
Common Stock, Shares, Issued 20.7M shares +7.35%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 272M USD +3.76%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -122M USD -141%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Additional Paid in Capital 513M USD +8.59%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 13.2M USD -25.7%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%